CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas
Open accessPublished version of a preprint
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: Angiosarcomas are soft tissue sarcomas with endothelial differentiation and vasoformative capacity. Most angiosarcomas show strong constitutive expression of the endothelial adhesion receptor CD31/PECAM-1 pointing to an important role of this molecule. However, the biological function of CD31 in angiosarcomas is unknown. Experimental Design: The expression levels of CD31 in angiosarcoma cells and its effects on cell viability, colony formation, and chemoresistance were evaluated in human angiosarcoma clinical samples and in cell lines through isolation of CD31high and CD31low cell subsets. The redox-regulatory CD31 function linked to YAP signaling was determined using a CD31-blocking antibody and siRNA approach and was further validated in CD31-knockout endothelial cells. Results: We found that most angiosarcomas contain a small CD31low cell population. CD31low cells had lost part of their endothelial properties and were more tumorigenic and chemoresistant than CD31high cells due to more efficient reactive oxygen species (ROS) detoxification. Active downregulation of CD31 resulted in loss of endothelial tube formation, nuclear accumulation of YAP, and YAP-dependent induction of antioxidative enzymes. Addition of pazopanib, a known enhancer of proteasomal YAP degradation resensitized CD31low cells for doxorubicin resulting in growth suppression and induction of apoptosis. Conclusions: Human angiosarcomas contain a small aggressive CD31low population that have lost part of their endothelial differentiation programs and are more resistant against oxidative stress and DNA damage due to intensified YAP signaling. Our finding that the addition of YAP inhibitors can resensitize CD31low cells toward doxorubicin may aid in the rational development of novel combination therapies to treat angiosarcomas. Clin Cancer Res; 24(2); 460–73. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Endothelial cells with low CD31 expression have been shown to exhibit increased proliferative potential and enhanced resistance to oxidative stress compared to cells with high CD31 expression [29].”
From Donor Variability Alters the Characteristics of Human Brain Microvascular Endothelial Cells (2025) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Slug is a key transcriptional repressor of CD31 and VE-cadherin, coordinating the transition of endothelial into mesenchymal fibroblast-like cells (46).”
BackgroundInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Elucidation of a universal size-control mechanism in Drosophila and mammals
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., & Pan, D. (2007) · Cell · doi:10.1016/j.cell.2007.07.019 · Cited by 2,370
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145
Lei, Q.-Y., Zhang, H., Zhao, B., Zha, Z.-Y., Bai, F., Pei, X.-H., Zhao, S., Xiong, Y., & Guan, K.-L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01874-07 · Cited by 924
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843 · cited 2×
“Recently, it was shown that Akt can lead to Ser127phosphorylation independently fromHippokinases LATS1/2 (29, 43).”
BackgroundNovel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
Antonescu, C. R., Le Loarer, F., Mosquera, J., Sboner, A., Zhang, L., Chen, C., Chen, H., Pathan, N., Krausz, T., Dickson, B. C., et al. (2013) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22073 · Cited by 597
YAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
Errani, C., Zhang, L., Sung, Y. S., Hajdu, M., Singer, S., Maki, R. G., Healey, J. H., & Antonescu, C. R. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20886 · Cited by 553
Fury, M. G., Antonescu, C. R., Van Zee, K. J., Brennan, M. E., & Maki, R. G. (2005) · The Cancer Journal · doi:10.1097/00130404-200505000-00011 · Cited by 413
Research works printed but not linked: 1
- Weiss, 2008, Malignant vascular tumors, 703
Cited by
Emerging role of NRF2 in ROS-mediated tumor chemoresistance
Xue, D., Zhou, X., & Qiu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110676 · Cited by 191
Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 167
Zhou, Y. M., Wang, Y., Zhou, W., Chen, T., Wu, Q., Chutturghoon, V. K., Lin, B., Geng, L., Yang, Z., Zhou, L., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0898-7 · Cited by 129
The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry
Azad, T., Ghahremani, M., & Yang, X. (2019) · Cells · doi:10.3390/cells8050407 · Cited by 116
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
Metadata
- Authors
- Venkataramani, V., Küffer, S., Cheung, K. C. P., Jiang, X., Trümper, L., Wulf, G. G., & Ströbel, P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Universitätsmedizin Göttingen (DE)
- Queen Mary University of London (GB)
- Corresponding author
- Venkataramani, Vivek
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2018-01-15
- Volume
- 24
- Issue
- 2
- Pages
- 460-473
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC7464789
- OpenAlex
- W2766581018
- Cited by
- 50
- References
- 46
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 7 · 2018: 5
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Funders
- NCI (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Keywords
- angiosarcoma, YAP signaling, chemoresistance, doxorubicin resistance, pazopanib, reactive oxygen species scavenging, oxidative stress, endothelial differentiation, tumor heterogeneity, antioxidant enzymes, combination therapy
- MeSH terms
- Catalase, Cell Survival, Doxorubicin, Hemangiosarcoma, Humans, Immunohistochemistry, Models, Biological, Neovascularization, Pathologic, Oxidation-Reduction, Biomarkers, Gene Expression, Oxidative Stress, Drug Resistance, Neoplasm, Platelet Endothelial Cell Adhesion Molecule-1, RNA, Small Interfering, Endothelial Cells, Cell Line, Tumor, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1778
- The paper
- Venkataramani, V., Küffer, S., Cheung, K. C. P., Jiang, X., Trümper, L., Wulf, G. G., & Ströbel, P. (2018). CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.